# Sanofi: Form 20-F for the period ended Dec 31, 2023

- Company: [Sanofi](/companies/sny.md) (CIK 1121404)
- Form: 20-F
- Filed: 2024-02-23
- Accepted by EDGAR: Feb 23, 2024, 11:15 ET
- Period: 2023-12-31
- Accession: 0001121404-24-000009
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1121404/000112140424000009/sny-20231231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1121404/000112140424000009/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 12 months, 2023-01-01 to 2023-12-31 | EUR 14.24bn | ifrs-full:CostOfSales |
| Gross profit | 12 months, 2023-01-01 to 2023-12-31 | EUR 32.21bn | ifrs-full:GrossProfit |
| Operating income | 12 months, 2023-01-01 to 2023-12-31 | EUR 7.88bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2023-01-01 to 2023-12-31 | EUR 1.60bn | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2023-01-01 to 2023-12-31 | EUR 5.40bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Operating cash flow | 12 months, 2023-01-01 to 2023-12-31 | EUR 10.26bn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | at 2023-12-31 | EUR 8.71bn | ifrs-full:CashAndCashEquivalents |
| Total assets | at 2023-12-31 | EUR 126.46bn | ifrs-full:Assets |
| Shareholders' equity | at 2023-12-31 | EUR 74.04bn | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | at 2023-12-31 | 1,264,799,969 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1121404/000112140424000009/sny-20231231.htm

Filed Feb 23, 2024.
Source: SEC EDGAR, the filing index for accession 0001121404-24-000009. Last ingested by Listed: Nov 5, 2026, 12:26 ET. No prices; not investment advice.
